"If your NSCLC has a high level of PD-L1, keytruda may be your first treatment option rather than chemotherapy, which is a historical change and future trend, but most patients cannot be treated due to low PD-1."

 

This is Professor Fu Yangxin's affirmation of the trend of PD-1 / PD-L1 antibody drugs in cancer treatment at the first Dawan District tumor cell immunotherapy forum in China. However, due to the low content of PD-1 in most patients, car-t cell therapy has become a popular immunotherapy.

 

Car-t cell therapy is another new technology after targeted therapy, which is deeply valued by the industry and loved by the capital market. In order to seize the opportunity of the era in the wave of immunotherapy, on November 20, China's first Dawan tumor cell immunotherapy forum was successfully held in Wanli Sea View Hotel, Hong Kong.

 

According to Zhitong financial app, Hong Kong listed company China biotechnology service (08037) is one of the sponsors. It has jointly held this forum with the sponsors of Shenzhen life science and Biotechnology Association, Hong Kong Institute of immunology, CCB International (holding) and China Merchants Securities (Hong Kong). The sponsors include Hong Kong China M & A Association, Beijing Life Science Research Institute and China Merchants health Kang Industrial investment company, School of life science and technology, Shanghai Jiaotong University.